suchen
Generic filters

IBD

IBD

ASGE Journal Scan | IBD

Ileal and Rectal Ulcers Heal Slower and May Be More Refractory to Therapy Than Colonic Lesions in Crohn’s Disease

Researchers performed a post hoc analysis of endoscopic outcomes in participants of the pivotal SONIC trial that compared the efficacy of azathioprine, infliximab, and the

JETZT ANSEHEN

IBD

Low Incidence of Colorectal Cancer After Endoscopic Dysplasia Resection in Patients With IBD

Given the paucity of high-quality outcome data, the optimal management of polypoid and/or nonpolypoid colonic lesions in IBD is an ongoing debate. Guidelines recommend that

JETZT ANSEHEN

ASGE Journal Scan | IBD

Recycled Precolectomy Anti-Tumor Necrosis Factor Does Not Work for Chronic Pouchitis

Following total proctocolectomy with restorative ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC), about one-third of patients develop chronic pouchitis. Treatment of antibiotic-refractory and Crohn’s

JETZT ANSEHEN

ASGE Journal Scan | IBD

Relapse Half as Likely With Ulcerative Colitis in Clinical and Endoscopic Remission Than Clinical Remission with Mild Endoscopic Disease Activity

The current treatment target in ulcerative colitis (UC) is clinical and endoscopic remission, defined by patient-reported outcomes and a Mayo endoscopic subscore of 0 or

JETZT ANSEHEN

ASGE Journal Scan | IBD

Postoperative Endoscopic Recurrence of Ileal Lesions, Not Anastomotic Lesions, More Likely to Predict Long-Term Outcomes in Crohn’s Disease

Early endoscopic recurrence of Crohn’s disease (CD) following ileocolonic resection predicts clinical recurrence, the need for therapy escalation, and repeat surgery. The significance of mild

JETZT ANSEHEN

ASGE Journal Scan | IBD

Fecal Microbiota Transplantation Shows Promise for IBS in the Most Recent Randomized Controlled Trial

Alterations of the gut microbiota in irritable bowel syndrome (IBS) have been described. Observational studies on fecal microbiota transplantation (FMT) aiming to restore eubiosis have

JETZT ANSEHEN

ASGE Journal Scan | IBD

High-Dose Vitamin D Does Not Prevent Postoperative Recurrence of Crohn’s Disease

The optimal vitamin D level for patients with IBD is highly debated. While a level >20 ng/L is sufficient for bone health even in high-risk

JETZT ANSEHEN

ASGE Journal Scan | IBD

No Benefit From Antibiotics for Uncomplicated Diverticulitis

A randomized, placebo-controlled, double-blinded trial showed no benefit from antibiotic therapy for the management of uncomplicated acute diverticulitis.  Hospitalized patients (N=180) in New Zealand and

JETZT ANSEHEN

ASGE Journal Scan | IBD

Daily 81 mg of Aspirin OK in Patients With IBD

Monika Fischer, MD, reviewing Patel P, et al. Inflamm Bowel Dis 2020 Mar 27. Nonsteroidal anti-inflammatory medications are known to increase the risk of IBD

JETZT ANSEHEN

ASGE Journal Scan | IBD

Achieving Deep Remission Early, No Matter How, Is Best Way to Decrease Crohn’s Disease Progression

Monika Fischer, MD, reviewing Ungaro RC, et al. Gastroenterology 2020 Mar 26. The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program recommended deep remission

JETZT ANSEHEN

ASGE Journal Scan | IBD

Serum Biomarkers Predict Crohn’s Disease Diagnosis 5 Years in Advance, but Not Ulcerative Colitis

Monika Fischer, MD, reviewing Torres J, et al. Gastroenterology 2020 Mar 9. Early intervention appears to be the key to mitigating severe complications of Crohn’s

JETZT ANSEHEN

ASGE Journal Scan | IBD

Shortening Ustekinumab Interval to Every 4 Weeks Associated With Increased Rates of Clinical and Biological Remission in Patients With Crohn’s Disease

Monika Fischer, MD, reviewing Ollech JE, et al. Clin Gastroenterol Hepatol 2020 Feb 25. This single-center retrospective study evaluated the outcomes of 110 patients with

JETZT ANSEHEN

ASGE Journal Scan | IBD

Healthy Lifestyle Recommended for General Public Associated With Significant Survival in Adult-Onset IBD

Monika Fischer, MD, reviewing Lo CH, et al. Clin Gastroenterol Hepatol 2020 Mar 3. Several studies in the non-IBD population have shown that a healthy

JETZT ANSEHEN

ASGE Journal Scan | IBD

First Selective Oral Jak1 Inhibitor Induces Remission in Ulcerative Colitis

Monika Fischer, MD, reviewing Sandborn WJ, et al. Gastroenterology 2020 Feb 21.  Upadacitinib, a selective Janus kinase 1 (Jak1) inhibitor (60-fold selective for Jak1 over

JETZT ANSEHEN

ASGE Journal Scan | IBD

Anti-Tumor Necrosis Factor Should Be Considered for Ulcerative Proctitis Refractory to Conventional Therapy

Monika Fischer, MD, reviewing Pineton de Chambrun G, et al. Clin Gastroenterol Hepatol 2020 Mar. Treatment of ulcerative proctitis that is unresponsive to mesalamine and

JETZT ANSEHEN

ASGE Journal Scan | IBD

Predictors of Colectomy at 1 Year in Severe Ulcerative Colitis

Monika Fischer, MD, reviewing Le Baut G, et al. Clin Gastroenterol Hepatol 2020 Jan 9. A French IBD consortium studied 270 hospitalized patients with severe

JETZT ANSEHEN

ASGE Journal Scan | IBD

Mediterranean Diet May Reduce the Risk of Crohn’s Disease Onset in Middle-Aged or Older Adults

Monika Fischer, MD, reviewing Khalili H, et al. Gut 2019 Jan 3. A large prospective cohort study from Sweden (N=83,147; age range, 45-79 years; mean

JETZT ANSEHEN

ASGE Journal Scan | IBD

Higher Infliximab Trough Concentrations Needed for Mucosal Healing in Crohn’s Disease Than Previously Suggested

Monika Fischer, MD, reviewing Dreesen E, et al. Clin Gastroenterol Hepatol 2020 Jan 16. The previously published TAILORIX study failed to show benefits from proactive therapeutic drug

JETZT ANSEHEN

ASGE Journal Scan | IBD

Microscopic Colitis Increases the Risk of Late-Onset IBD

Monika Fischer, MD, reviewing Khalili H, et al. Gastroenterology 2020 Jan 8. In a nationwide Swedish cohort study, the diagnosis of microscopic colitis (N=14,000) was

JETZT ANSEHEN

ASGE Journal Scan | IBD

Inpatient Fecal Microbiota Transplantation Program Decreases C difficile-Related Mortality and Colectomy

Monika Fischer, MD, reviewing Cheng YW, et al. Clin Gastroenterol Hepatol 2020 Jan 7. Severe and fulminant forms of C difficile infection (CDI) are often refractory to

JETZT ANSEHEN

ASGE Journal Scan | IBD

Crohn’s Disease Patients with HLA-DQA1*05 Allele at Increased Risk of Antidrug Antibody Development

Monika Fischer, MD, reviewing Sazonovs A, et al. Gastroenterology 2020 Jan.  In this genome-wide association study, 1240 patients with biologic-naive Crohn’s disease were treated with

JETZT ANSEHEN

ASGE Journal Scan | IBD

Proactive Versus Reactive Monitoring of Anti-TNF Drug Levels: A Randomized Controlled Trial

Kenneth R. McQuaid, MD, FASGE reviewing Assa A, et al. Gastroenterology 2019 Oct. In IBD, loss of response to anti-TNF therapy is more likely with

JETZT ANSEHEN

ASGE Journal Scan | IBD

Vedolizumab Is More Efficacious Than Adalimumab for UC in a Head-to-Head Trial

Monika Fischer, MD, FASGE reviewing Sands BE, et al. N Engl J Med 2019 Sep 26. A head-to-head phase 3 trial involving patients with moderately

JETZT ANSEHEN

ASGE Journal Scan | IBD

Ustekinumab Is Efficacious for Induction and Maintenance of UC

Monika Fischer, MD, FASGE reviewing Sands BE, et al. N Engl J Med 2019 Sep 26. Ustekinumab, an antagonist of the p40 subunit of interleukin-12

JETZT ANSEHEN

ASGE Journal Scan | IBD

Subcutaneous Vedolizumab Is as Effective as Intravenous Formulation for Maintenance of Remission in Patients With Ulcerative Colitis

Vedolizumab is a highly effective and safe treatment option for patients with moderately severe and severe ulcerative colitis, with over 40% of patients achieving clinical

READ MORE

ASGE Journal Scan | IBD

Therapeutic Drug Monitoring of Vedolizumab: Should Trough Levels Be Measured…and When?

In IBD patients treated with anti-TNF agents, therapeutic drug monitoring (TDM) is commonly used to optimize therapy, reduce risk of antibody formation, and determine mechanisms

READ MORE

Scroll to Top